Clik here to view.
百奥赛图与Pheon Therapeutics达成授权协议
中国北京和英国伦敦 (美国商业资讯)– 百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK），一家专注于创新治疗性抗体发现的国际性生物技术公司，今天宣布与专注抗体药物偶联物（ADC）开发的Pheon...
View ArticleClik here to view.
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
BEIJING & LONDON Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an...
View ArticleClik here to view.
バイオサイトジェン・ファーマシューティカルズ、Pheon Therapeuticsとライセンス契約を締結
北京 & ロンドン （ビジネスワイヤ） — 新たな抗体治療薬の発見に重点的に取り組む世界的バイオテクノロジー企業であるバイオサイトジェン・ファーマシューティカルズ（北京）（以下「バイオサイトジェン」、HKEX: 02315）は、Pheon Therapeutics...
View ArticleClik here to view.
NTHU Hospital BOT Project in Taoyuan with over NT$10 Billion of Investment by...
HSINCHU, TAIWAN National Tsing Hua University (NTHU) in Taiwan signed a BOT hospital contract with privately owned Kaohsiung Medical University (KMU) on July 4th, with NTHU President W. John Kao...
View ArticleClik here to view.
Celmatix宣布在新型口服生育药物计划方面取得突破
纽约 (美国商业资讯)– Celmatix是一家专注于卵巢生物学的领先女性健康生物技术公司。该公司今天宣布在其最新药物项目中识别到具有开发潜质的早期先导药物，以开发世界上第一种口服FSH受体激动剂药物。这种创新的研究产品有潜力彻底改变生育疗法。此次宣布恰逢目前正在丹麦哥本哈根举行的欧洲人类生殖与胚胎学学会（European Society of Human Reproduction and...
View ArticleClik here to view.
Wyss Center任命Craig Cook博士为新任商务拓展与授权主管
日内瓦 (美国商业资讯)– Wyss Center是一家领先的非营利性研究中心，致力于创新和推动应对神经和精神健康疾病方面的技术和疗法。该机构高兴地宣布，任命医学博士兼工商管理硕士Craig Cook加入领导团队，担任商务拓展与授权主管。Cook博士在生物技术、医疗技术和临床医学领域拥有超过25年的丰富领导经验和企业管理专长。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Wyss Centerが事業開発・ライセンス部門の新責任者にクレイグ・クックを任命
ジュネーブ （ビジネスワイヤ） — 神経疾患および精神疾患に対する技術、治療法の革新・加速を目的として設立された非営利研究機関であるWyss...
View ArticleClik here to view.
China Industry-University-Research-Medicine Shines at the Top of the World:...
SINGAPORE “In 2015, we made our first appearance in Vancouver WCD with the main brand WINONA. After eight years, WINONA has now become the leading brand of functional skin care products in China....
View ArticleClik here to view.
The World Congress of Dermatology Closed, WINONA Propels Chinese Brand Appeal...
KUNMING, China On July 8th, the 25th World Congress of Dermatology (WCD), referred to as the “Olympics of the Dermatology,” concluded in Singapore, with the Chinese top dermatology skin care brand...
View ArticleClik here to view.
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2...
HANGZHOU, CHINA HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the first patient has been dosed in a...
View ArticleClik here to view.
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly,...
BREA, Calif. & TOKYO Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a...
View ArticleClik here to view.
SYNERGEN Health Announces Appointment of Robert Marinich as SVP of Sales
DALLAS & COLOMBO, Sri Lanka SYNERGEN Health, an industry-leading provider of technology-enabled revenue cycle services and solutions for healthcare organizations, today announced the appointment...
View ArticleClik here to view.
Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND)...
HANGZHOU, China Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ...
View ArticleClik here to view.
Santen Agrees to Licensing Agreements and Asset Transfer for its...
OSAKA, Japan Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an...
View ArticleClik here to view.
New Data Shows Advantages of Rapid Medical’s COMANECI™ Embolization Assist...
YOKNEAM, Israel & MIAMI Rapid Medical™, a leading developer of advanced neurovascular devices, today announced new clinical data showing significant advantages of its novel COMANECI™...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
Kenvue启动季度现金股息计划
新泽西州斯基尔曼 (美国商业资讯)– 全球营收规模最大的单一业务消费者健康公司Kenvue Inc. (NYSE: KVUE) (“Kenvue”)今日宣布，公司董事会已决定在2023年第三季度向公司普通股派发每股0.20美元的股息。 首席执行官兼董事Thibaut...
View ArticleClik here to view.
ケンビュー、四半期現金配当を発表
米ニュージャージー州スキルマン （ビジネスワイヤ） — 売上高において世界最大のコンシューマー ヘルス専業企業であるケンビュー（NYSE：KVUE）は、同社取締役会が2023年第3・四半期に支払われる配当金を普通株式1株あたり0.20ドルとする旨を決議したと発表しました。...
View Article